The global head and neck squamous cell carcinoma (HNSCC) market is estimated to garner a revenue of ~USD 6 Billion by the end of 2035 by growing at a CAGR of ~9% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of ~USD 2 Billion in the year 2022. The growth of the market can be attributed to the increasing cases of head and neck cancer throughout the world. For instance, head and neck cancer claimed the lives of nearly 280,605 people globally in 2020. Further, the worldwide surging demand for combination therapy for the effective treatment of head and neck cancer is also estimated to radically spur the market growth during the forecast period.
In addition to these, factors that are believed to fuel the market growth of head and neck squamous cell carcinoma (HNSCC) include the escalating use of tobacco among the people which is boosting cases of head and cancer throughout the world. Based on the World Health Organization report, in 2020, 36.7% of all men and 7.8% of all women consumed tobacco. This represents 22.3% of the world's population. Additionally, the growing advancement in the screening procedure of cancer and a very prominent presence of drugs comprising Avelumab, Ipilimumab, Atezolizumab, and so on are also predicted to present the potential for market expansion over the projected period. In addition to this, worldwide escalating demand for non-surgical therapeutics comprising targeted therapy, chemotherapy, and so on is also anticipated to spur market growth throughout the projected time frame.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~9% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 6 Billion |
|
Regional Scope |
|
Growth Drivers
Growing R&D and Approvals for Cancer Drugs and Treatment - Head and neck cancers are treated by using single or combination therapies. Owing to the presence of different types of head and neck cancers, healthcare providers are increasingly working on developing drugs and treatments which apply to treating the disease. Currently, several cancer vaccines for treating head and cancer drugs are under different phases of clinical trials and pharmaceutical manufacturers are spending heavily on research and development to come up with a proper cure for the disease. For instance, the Food and Drug Administration (FDA) has approved several drugs for treating head and neck cancer. Some of them include Bleomycin Sulfate, Cetuximab, Docetaxel, Erbitux, and others.
Escalating Consumption of Alcohol – Presently, a huge ratio of people have been consuming alcohol and getting the addiction to it. Alcohol is a potent chemical that can negatively impact nearly every part of the human body, namely the heart, bones, and brain. Also, excessive drinking may raise blood pressure and cholesterol levels. Moreover, excessive drinking can increase the risk of mouth cancer and several other types of cancers. Therefore, the escalating consumption of alcohol is also anticipated to fuel market growth in the coming years. For instance, in the United Kingdom, around 49% of adults (aged 16) stated to consume alcohol at least once a week in 2019. Whereas, nearly 57% of men and 44% of women admitted they drank alcohol at least once a week.
Growing Adoption of Immune Therapeutics - Immune therapeutics or immunotherapy is provided to cancer patients as it possesses numerous benefits over other therapy types. With the growing concern for the increasing number of cancer cases, there is a growing need for treating these patients. Immunotherapy helps the body to combat cancer with its natural defenses. The process further slows or stops the growth of the cancer cells and stops it from spreading. For instance, based on a clinical study estimation conducted in 2020, approximately 44% of cancer patients in the United States were in need of ICI therapy, and approximately 14% of patients responded to it. Such a factor is therefore anticipated to drive the growth of the global head and neck squamous cell carcinoma (HNSCC) treatment and drugs market during the forecast period.
An Upsurge in Human Papillomavirus (HPV) Infection Cases - Human papillomavirus (HPV) infection is a viral infection that is usually transmitted during intercourse and causes growths on the skin or mucous membranes (warts). HPV also spreads through close skin-to-skin contact during sexual intercourse. A person infected with HPV can infect another person even if they exhibit no symptoms or signs of infection. Thus, HPV may infect the mouth and throat, leading to oropharyngeal cancer that spreads to the back of the throat, including the base of the tongue and tonsils. As per recent estimations, more than 13 million new cases of HPV infection are detected in the United States each year. Hence, the boost in HPV cases is also projected to proliferate the market growth during the forecast period.
Worldwide Surge in Healthcare Expenditure - According to the World Bank report, worldwide healthcare expenditure grew by 9.83% in 2019.
Challenges
The global head and neck squamous cell carcinoma (HNSCC) market is segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, retail, and online pharmacies. Out of these three types of segments, the hospital pharmacies segment is estimated to gain the largest market share of about ~55% in the year 2035. The growth of the segment can be attributed to the increasing number of cancer patients visiting the hospital for treatments, and therefore they need HNSCC drugs at the hospital premises. For instance, from 2015 to 2019, the number of cancer patients who visited the emergency department in Korea reached around 1,473,120. Nearly 55% of cancer-related ED visits ended in hospitalization, with 6% in ICU, and 10% died in the hospitals. On the other hand, several cancer treatment drugs are restricted for sale on online platforms or even to retail pharmacy outlets. As a result, these restricted drugs are available only in hospital pharmacies, which is anticipated to drive the growth of the segment during the forecast period.
The global head and neck squamous cell carcinoma (HNSCC) market is also segmented and analyzed for demand and supply by drug class into immunotherapy, chemotherapy, and targeted therapy. Amongst these three segments, the immunotherapy segment is expected to garner a significant share of around ~60% in the year 2035. The growth of the segment can be attributed to the significantly growing awareness among people regarding the effectiveness and advantages of cancer immunotherapy over chemotherapy is anticipated to fuel the segment’s growth over the forecast period. Furthermore, the surge in drug trials, coupled with the augmenting ratio of novel drugs approval from the authorities such as the FDA and EMA is also estimated to drive the segment growth further during the projected time frame. For instance, Nivolumab (Opdivo) and Pembrolizumab (Keytruda), are two PD-L1 inhibitors, licensed for the treatment of patients with head and neck cancer. Whilst, Dostarlimab (Jemperli) is under phase II clinical trials for head and neck squamous cell carcinoma that has progressed or resurfaced. On the other hand, the chemotherapy segment is projected to witness a notable CAGR during the forecast period, owing to the rising adoption of chemotherapy along with radiation therapy amongst cancer patients worldwide. Moreover, the escalating usage of chemotherapy with the combination of other drugs and therapy has been delivering good outcomes. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global head and neck squamous cell carcinoma (HNSCC) market includes the following segments:
|
By Drug Class |
|
|
By Distribution Channel |
|
The North American head and neck squamous cell carcinoma (HNSCC) market, amongst the market in all the other regions, is projected to hold the largest market share of about ~52% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of head and neck cancer backed by the surging ratio of alcohol, and tobacco consumption in people in the region. For instance, around 56,000 cases of oral and pharyngeal cancer are diagnosed in the United States each year, leading to over 12,000 deaths each year. Moreover, owing to the presence of a strong healthcare network, and the availability of numerous key players in the region, the market for head and neck squamous cell carcinoma (HNSCC) treatment and drugs is anticipated to display significant growth in the North American region. In addition to this, high awareness among people regarding the disease, along with the presence of favorable reimbursement policies and the availability of quality medical facilities are some more factors anticipated to boost the market growth further throughout the forecast period in the region.
The Asia Pacific head and neck squamous cell carcinoma (HNSCC) market, amongst the market in all the other regions, is projected to hold the second largest share of about ~29% during the forecast period. The growth of the market can be attributed majorly to the surging population, coupled with the significant increase in the geriatric population, the growing prevalence of smoking, and escalating consumption of alcohol among people in the region. For instance, in 2020, the predicted frequency of any tobacco product consumption among men was around 41% in Malaysia, 38% in Thailand, 47% in South Korea, 30% in Singapore, 15% in Australia, and 10% in Hong Kong. In addition, the escalating prescription of immunotherapy drugs for the effective treatment of several kinds of head and neck cancer is also anticipated to boost the market growth during the forecast period.
Further, the market in the European region, amongst the market in all the other regions, is projected to hold a considerable share of about ~10% by the end of 2035. The growth of the market can be attributed majorly to the surging ratio of head and neck cancer among people especially men in the region. Moreover, the escalating consumption of alcohol among youngsters is also projected to spike the market growth in the region in the coming years. In addition to this, the usage of tobacco and tobacco products by a large pool of the European population has increased in recent years. For instance, in 2021, almost 188 million people, or 28% of the adult population of Europe, were tobacco users. This, as a result, is also estimated to boost the market growth further during the forecast period in the region.
Immutep Limited announced that it has completed the recruitment of patients having head and neck cancer and has safely dosed them for stage 2 of Part C of its Two ACTive Immunotherapies (TACTI-002) Phase II study trials.
Checkpoint Therapeutics, Inc. announced that it has expanded its partnership with Samsung Biologics Co., Ltd. for manufacturing the anti-PD-L1 antibody, cosibelimab on a commercial scale.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?